TrialBritish journal of cancer2020

A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer.

Kosei Hasegawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.